Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral, Rectal, Vaginal, Topical, Transdermal, Sublingual, Subcutaneous, Intravenous, Intramuscular, Insufflation, Intrathecal, Intranasal
01
Overview
(4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid, also known as 4-HDHA or 4-OHDHA, is a bioactive metabolite derived from the omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA). It is formed through the 5-lipoxygenase (5-LOX) enzymatic pathway. This small molecule acts as a potent agonist of peroxisome proliferator-activated receptor gamma (PPARγ), mediating antiangiogenic and anti-inflammatory effects. Research indicates that 4-HDHA directly inhibits endothelial cell proliferation and sprouting angiogenesis, suggesting its potential in treating conditions characterized by pathological neovascularization, such as proliferative retinopathy. It has also demonstrated anti-inflammatory properties by suppressing inflammatory gene expression and alleviating symptoms in models of colitis.
- Other names
- 4-HDHA4-OHDHA(5E,7Z,10Z,13Z,16Z,19Z)-4-Hydroxy-5,7,10,13,16,19-docosahexaenoic acidCHEMBL427140CHEMBL-427140CHEMBL 427140IFRKCNPQVIJFAQ-PQVBWYSWSA-NDB-214967DB214967DB 214967HY-130289HY130289HY 130289CS-0106482CS0106482CS 0106482Q27140026Q-27140026Q 27140026
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid.